The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
May 2, 2018
Effective May 16, 2018, teaching permit holders are exempt from the general continuing education (CE) requirement. Rule 64B5-7.005, F.A.C. was amended to align with the full time faculty exemption in Rule 64B5-12.0135, F.A.C. This amendment does not exempt a teaching … Continue reading